Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 6
Submit an article Journal homepage
245
Views
3
CrossRef citations to date
0
Altmetric
Letters to the Editor

Effect of post-treatment MRD status on subsequent outcomes according to chemotherapy intensity in acute myeloid leukemia (AML)

Michael J. Hochmana Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0003-0594-154X
ORCID Icon,
Megan Othusa Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Roland B. Waltera Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Carole Shawb Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Kelda Gardnera Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
,
Mary-Elizabeth M. Percivala Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-7016-951X
ORCID Icon,
Anna B. Halperna Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
,
Paul C. Hendriea Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA
,
Brenda M. Sandmaiera Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USAORCID Iconhttps://orcid.org/0000-0002-9767-9739
ORCID Icon &
Elihu H. Esteya Department of Medicine, Division of Hematology, University of Washington, Seattle, WA, USA;b Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]
 show all
Pages 1532-1535 | Received 29 Sep 2020, Accepted 30 Jan 2021, Published online: 22 Mar 2021

References

  • Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD working party. Blood. 2018;131(12):1275–1291.
  • Buccisano F, Hourigan CS, Walter RB. The prognostic significance of measurable (“minimal”) residual disease in acute myeloid leukemia. Curr Hematol Malig Rep. 2017;12(6):547–556.
  • Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. 2017;102(5):865–873.
  • Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia: time to move toward a minimal residual disease-based definition of complete remission? J Clin Oncol. 2016;34(4):329–336.
  • Ravandi F, Walter RB, Freeman SD. Evaluating measurable residual disease in acute myeloid leukemia. Blood Adv. 2018;2(11):1356–1366.
  • Freeman SD, Hourigan CS. MRD evaluation of AML in clinical practice: are we there yet? Hematology Am Soc Hematol Educ Program. 2019;2019(1):557–569.
  • Chen X, Xie H, Wood BL, et al. Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia. J Clin Oncol. 2015;33(11):1258–1264.
  • Boddu P, Jorgensen J, Kantarjian H, et al. Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse. Leukemia. 2018;32(1):241–244.
  • Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100(7):2292–2302.
  • Chen X, Othus M, Wood BL, et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leuk Lymphoma. 2020:1–7. DOI:https://doi.org/10.1080/10428194.2020.1861267
  • Halpern AB, Othus M, Huebner EM, et al. Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia. 2018;32(11):2352–2362.
  • Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2003;21(24):4642–4649.
  • Zhou Y, Wood BL. Methods of detection of measurable residual disease in AML. Curr Hematol Malig Rep. 2017;12(6):557–567.
  • Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
  • Papaemmanuil E, Döhner H, Campbell PJ. Genomic classification in acute myeloid leukemia. N Engl J Med. 2016;375(9):900–901.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.